90 abstinent chronic alcoholics were randomly treated with 800 mg of arginine pyroglutamate, piracetam and placebo three times a day, according to a double blind study programme. The treatment lasted three months. Certain exploratory tests showed an improvement in visual/spatial perception for the group treated with arginine pyroglutamate. It is emphasized that this drug is useful as an associated medication in ensuring the early recovery of cognitive defects in abstinent chronic alcoholics. The γ glutamyl transpeptidase (γ GT) count also showed a statistically significant decrease: this is considered the most significant test in screening for alcoholism, and is also the most frequent indicator of non-cirrhotic alcoholic hepatitis.
|Translated title of the contribution||Reversibility of cognitive disorders in chronic alcoholics undergoing abstinence: Effects of arginine pyroglutamate|
|Number of pages||8|
|Publication status||Published - 1985|
ASJC Scopus subject areas
- Psychiatry and Mental health